Literature DB >> 1858154

A randomized prospective trial comparing cyclosporine monotherapy with triple-drug therapy in renal transplantation.

A Tarantino1, A Aroldi, L Stucchi, G Montagnino, L Mascaretti, A Vegeto, C Ponticelli.   

Abstract

In a prospective trial 151 recipients of renal transplants were randomly assigned to treatment with CsA alone (74 patients) and to low dose of AZA, prednisolone, and CsA (77 patients). At two years, graft survival was 84% for the monotherapy and 90% for the triple therapy. This difference was not statistically significant. The number of rejection episodes was similar in the two groups, but the severity of rejection was significantly worse among the patients on monotherapy. More kidneys were lost because of rejection (6 versus 3), and a higher number of methylprednisolone pulses was used for treating rejection (5.2 +/- 2.3 versus 4.3 +/- 2.9; P = 0.0077). CsA nephrotoxicity episodes were more frequent among patients on monotherapy (23 versus 7; P less than 0.02). Infectious episodes were equally distributed between the two groups. Creatinine clearance was poorer in the monotherapy-treated patients at the third month (42 +/- 16 ml/min versus 48 +/- 15 ml/min; P = 0.02), but no differences were observed between the two groups since the sixth month after transplantation. Many patients on monotherapy required changes in maintenance therapy. In fact, one patient was switched to conventional immunosuppression because of Cremophor-induced anaphylaxis. Another patient who developed Kaposi's sarcoma 4 months after surgery was switched to steroids alone. Excluding 5 patients who lost their grafts a few days after transplantation, only 30 of 74 patients (40%) could be kept without steroids. We conclude that both the therapeutic protocols can give good results in renal allotransplantation; however, monotherapy could create some problems in keeping the balance between drug toxicity and significant immunosuppression. On the contrary, triple therapy is easier to handle, especially in the early posttransplant period when the differential diagnosis between acute rejection and CsA-related nephrotoxicity can be difficult even for a skilled clinician.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1858154     DOI: 10.1097/00007890-199107000-00011

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  10 in total

Review 1.  Immunosuppressive drugs in renal transplantation. A review of the regimens.

Authors:  J M Barry
Journal:  Drugs       Date:  1992-10       Impact factor: 9.546

2.  FK 506 conversion of renal allografts failing cyclosporine immunosuppression.

Authors:  M L Jordan; R Shapiro; C W Jensen; V Scantlebury; J Fung; A Tzakis; J McCauley; A Jain; J Demetrius; P Randhawa
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

3.  FK 506 salvage of renal allografts with ongoing rejection failing cyclosporine immunosuppression.

Authors:  M L Jordan; R Shapiro; C A Vivas; V P Scantlebury; F S Darras; G Carrieri; J McCauley; A J Demetris; P Randhawa; C Jensen
Journal:  Transplant Proc       Date:  1993-02       Impact factor: 1.066

4.  Tacrolimus rescue therapy for renal transplant rejection.

Authors:  M L Jordan; R Shapiro; R Naraghi; D Smith; C Vivas; H A Gritsch; V Scantlebury; P Randhawa; A J Demetris; J J Fung; T E Starzl
Journal:  Transplant Proc       Date:  1996-08       Impact factor: 1.066

Review 5.  Cyclosporin: a pharmacoeconomic evaluation of its use in renal transplantation.

Authors:  J E Frampton; D Faulds
Journal:  Pharmacoeconomics       Date:  1993-11       Impact factor: 4.981

Review 6.  Ocular side effects of anti-rheumatic medications: what a rheumatologist should know.

Authors:  V Peponis; V C Kyttaris; S E Chalkiadakis; S Bonovas; N M Sitaras
Journal:  Lupus       Date:  2010-02-09       Impact factor: 2.911

Review 7.  Calcineurin inhibitors in renal transplantation: what is the best option?

Authors:  Kazunari Tanabe
Journal:  Drugs       Date:  2003       Impact factor: 9.546

8.  FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression.

Authors:  M L Jordan; R Shapiro; C A Vivas; V P Scantlebury; P Rhandhawa; G Carrieri; J McCauley; A J Demetris; A Tzakis; J J Fung
Journal:  Transplantation       Date:  1994-03-27       Impact factor: 4.939

Review 9.  Corticosteroids in kidney transplant recipients. Safety issues and timing of discontinuation.

Authors:  A Tarantino; G Montagnino; C Ponticelli
Journal:  Drug Saf       Date:  1995-09       Impact factor: 5.606

10.  Steroid- and calcineurin inhibitor free immunosuppression in kidney transplantation: state of the art and future developments.

Authors:  Markus Giessing; Tom Florian Fuller; Max Tuellmann; Torsten Slowinski; Klemens Budde; Lutz Liefeldt
Journal:  World J Urol       Date:  2007-02-28       Impact factor: 3.661

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.